Reaction

Neoplasm Recurrence reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,353 reports · 119 co-occurring drugs

As of the last recalculation, Neoplasm Recurrence appears in 3,353 FAERS reports alongside 119 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 35.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Thiotepa	54	35.7	35.9
Vincristine Sulfate	149	33.0	33.1
Ifosfamide	102	30.4	30.5
Imatinib Mesylate	115	26.5	26.6
Cytarabine	235	26.0	26.1
Temozolomide	75	22.6	22.7
Busulfan	56	22.5	22.5
Blinatumomab	36	21.6	21.7
Doxorubicin Hydrochloride	105	20.6	20.6
Niraparib	64	18.2	18.3
Somatropin	201	18.0	18.0
Etoposide	200	17.9	17.9
Palbociclib	242	16.9	16.9
Dexamethasone Sodium Phosphate	27	16.6	16.7
Imatinib	46	16.4	16.4
Doxorubicin	204	15.1	15.1
Mercaptopurine	40	14.5	14.5
Bendamustine Hcl	35	14.1	14.2
Exemestane	46	13.5	13.5
Carboplatin	256	13.5	13.5
Fludarabine Phosphate	83	13.4	13.4
Encorafenib	21	13.2	13.3
Gemcitabine	80	12.9	12.9
Brentuximab Vedotin	21	12.8	12.8
Gemcitabine Hydrochloride	106	12.8	12.8
Bosutinib	18	12.5	12.5
Fulvestrant	63	12.0	12.1
Cyclophosphamide Injection, Solution	309	11.8	11.9
Cyclophosphamide	309	11.8	11.9
Cyclophosphamide For Injection	309	11.8	11.9
Docetaxel Anhydrous	123	11.7	11.7
Docetaxel	123	11.7	11.7
Cisplatin	139	11.5	11.5
Leucovorin Calcium	34	11.1	11.2
Melphalan	39	10.8	10.8
Melphalan Hydrochloride	41	10.3	10.3
Mesna Injection	13	9.8	9.8
Mesna	13	9.6	9.6
Anastrozole	56	9.6	9.6
Paclitaxel (Aibumin-Bound)	120	9.4	9.4
Goserelin	19	8.8	8.8
Cetuximab	43	8.6	8.6
Anastrozole Tablets	29	8.5	8.5
Lapatinib	21	8.4	8.5
Bendamustine Hydrochloride	16	8.3	8.3
Paclitaxel	126	8.2	8.2
Letrozole	77	7.9	7.9
Crizotinib	16	7.8	7.9
Bleomycin Sulfate	13	7.8	7.8
Polatuzumab Vedotin	12	7.7	7.7
Pazopanib Hydrochloride	33	7.6	7.6
Pertuzumab	32	7.4	7.4
Filgrastim	44	7.3	7.4
Letrozole Tablets	55	7.2	7.2
Olaparib	24	7.2	7.2
Sunitinib Malate	44	7.0	7.0
Hydrocortisone	97	6.9	6.9
Hydrocortisone 1%	72	6.8	6.8
Fluorouracil Cream, 0.5%	81	6.7	6.7
Anti-Itch	71	6.7	6.7
Anti-Pruritic	71	6.7	6.7
Antipruritic (Anti-Itch)	71	6.7	6.7
Cool Relief Gel With Aloe	71	6.7	6.7
Drs. Hydrocortisone	71	6.7	6.7
Hydrocortisone Continuous Spray	71	6.7	6.7
Hydrocortisone Spray	71	6.7	6.7
Anti-Itch Cream	71	6.7	6.7
Hydrocortisone Lotion	71	6.7	6.7
Hydrocortisone Cream 1%	71	6.7	6.7
Hydrocortisone Cream 1/2%	71	6.7	6.7
Hydrocortisone Cream	71	6.7	6.7
Fluorouracil	81	6.6	6.6
Octreotide Acetate	32	6.5	6.5
Trastuzumab	70	6.4	6.4
Hydrocortisone Acetate	73	6.4	6.4
Capecitabine	91	6.3	6.3
Gefitinib	9	6.2	6.2
Oxaliplatin	71	6.0	6.1
Testosterone	22	5.9	5.9
Pemetrexed	20	5.8	5.8
Lanreotide Acetate	7	5.6	5.6
Bevacizumab	104	5.3	5.4
Rituximab	172	5.3	5.3
Erlotinib	8	5.1	5.1
Axitinib	15	4.8	4.8
Dasatinib	27	4.5	4.5
Erlotinib Hydrochloride	9	4.5	4.5
Extended Phenytoin Sodium	12	4.5	4.5
Ado-Trastuzumab Emtansine	6	4.4	4.4
Rucaparib	6	4.2	4.2
Pemetrexed Disodium	25	4.1	4.1
Pegaspargase	8	4.1	4.1
Panitumumab	10	4.0	4.0
Trametinib	15	3.9	3.9
Dabrafenib	13	3.8	3.8
Nilotinib	18	3.8	3.8
Everolimus Tablets	10	3.7	3.7
Dexamethasone 1.5 Mg	164	3.6	3.6
Everolimus	29	3.6	3.6
Dexamethasone	164	3.6	3.6
Vismodegib	5	3.5	3.5
Venetoclax	33	3.3	3.4
Regorafenib	6	3.2	3.2
Fosaprepitant Dimeglumine	7	3.2	3.2
Durvalumab	10	3.1	3.1
Pembrolizumab	49	2.9	2.9
Carfilzomib	13	2.9	2.9
Alpelisib	4	2.9	2.9
Vemurafenib	5	2.6	2.6
Deferasirox	11	2.6	2.6
Atezolizumab	16	2.6	2.6
Ipilimumab	17	2.5	2.5
Irinotecan Hydrochloride	5	2.4	2.4
Azacitidine For	7	2.4	2.4
Nivolumab	36	2.3	2.3
Azacitidine	10	2.1	2.1
Acalabrutinib	4	2.1	2.1
Ixazomib	8	1.7	1.7
Pegfilgrastim	18	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.